Australian Pharmaceutical Industries Ltd
ASX:API
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.7), the stock would be worth AU$1.53 (0% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | AU$1.53 |
0%
|
| 3-Year Average | 0.7 | AU$1.53 |
+0%
|
| 5-Year Average | 0.7 | AU$1.53 |
+0%
|
| Industry Average | 2.4 | AU$5.52 |
+260%
|
| Country Average | 1.7 | AU$3.98 |
+160%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Australian Pharmaceutical Industries Ltd
ASX:API
|
753.8m AUD | 0.7 | 547.4 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 5 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.3B USD | 3.2 | 37.2 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.2B USD | 3.2 | 37.2 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.8B USD | 3.3 | 28.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
31.9B AUD | 4.7 | 34.6 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
61.9B CNY | 0.6 | 10.8 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
60B CNY | 2.2 | 21.2 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.9B USD | 1.2 | 22.5 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 4.7 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.7B HKD | 0 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Australian Pharmaceutical Industries Ltd
Glance View
Australian Pharmaceutical Industries Ltd. engages in the wholesale, product delivery, retail services, marketing programs and business advisory services. The company is headquartered in Melbourne, Victoria. The Company’s segments include Australia and New Zealand. The Australia segment is engaged in distribution of pharmaceutical, medical, health, beauty and lifestyle products and retail services to pharmacies, the purchase and sale of health, beauty and lifestyle products and services within the retail industry, including cosmetic products and non-invasive procedures. The New Zealand segment manufactures and owns rights for pharmaceutical medicines and consumer toiletries. The firm's brands include Priceline & Priceline Pharmacy, which is a health, beauty and wellbeing retailer; Soul Pattinson Chemist, which is a pharmacy brand; Pharmacist Advice, which offers professional service and advice; Club Premium, which is a club for independent pharmacies, and Pharmacy Best Buys, which offers a catalog program.
